5 Conclusion
In conclusion, although our meta-analysis showed little difference
between the prevalence of SARS-CoV-2 infections in patients with ARDs
and the global prevalence of SARS-CoV-2 infections, the prevalence of
COVID-19 in PsA was significantly higher than the global prevalence. The
use of DMARDs could reduce the risk
of being infected with COVID-19, but the use of GC increased this risk.
csDMARDs were associated with disease severity in COVID-19. bDMARDs,
especially anti-TNF, were associated with a reduced risk of severe
disease. GC is effective in patients with severe COVID-19-related
respiratory failure but may not have a benefit in patients with early or
mild disease.